The National Bleeding Disorders Foundation (NBDF) has named Mark Brimble, PhD, the 2026 recipient of the NBDF-Sanofi Career Development Award (CDA). Dr. Brimble is an assistant professor of Pediatrics at Washington University School of Medicine in St. Louis. His project will study how the immune system responds to adeno-associated virus (AAV) gene therapy in people with hemophilia A and B.
AAV gene therapy uses a harmless, engineered virus to deliver a working gene to the liver, offering a potential one-time treatment for hemophilia. The immune system can react against it, however, and those reactions vary from person to person.
Why does the immune system fight AAV gene therapy?
The immune system can react to AAV in two main ways. In some patients, T cells clear out the liver cells that received the gene, and the treatment’s benefit is lost. The body also builds lasting antibodies against the virus, which currently rules out a second treatment. “One significant challenge is that we currently can’t predict the precise nature of these responses within a particular individual prior to treatment,” Dr. Brimble said.
What is the focus of Dr. Brimble’s research?
Dr. Brimble’s project focuses on the T cell. Each T cell carries a protein on its surface called a T cell receptor (TCR). “TCRs are all slightly different, and the number of possible differences is more than the number of grains of sand on earth,” said Dr. Brimble. That diversity lets the body fight infections it has never encountered before.
His team will study TCR diversity to learn why AAV gene therapy succeeds or fails. A person has roughly half a trillion T cells, but a 1 ml blood sample lets researchers examine about 500,000 of them, a snapshot of what is happening in the body. Using blood samples from people treated with hemophilia gene therapy, the team will identify TCRs that appear only after a treatment is given and look at what issues they caused.
The project will begin with samples from the first successful hemophilia B gene therapy trial, with the aim of pinpointing the specific pieces of the therapy, called epitopes, that T cells react to.
“We know surprisingly little about what specifically causes harmful T cell responses in AAV gene therapy patients,” Dr. Brimble said. “This could eventually lead to gene therapies designed to avoid those triggers or are chosen to match a person’s immune genetic background. The goal is more predictable, longer-lasting benefit and the potential option to be treated again.”
Why this award matters
The NBDF-Sanofi Career Development Award supports investigators committed to bleeding disorders research, with a focus on innovative projects that advance new technologies or therapies. NBDF provides up to $70,000 per year for up to three years, and recipients are expected to spend at least 75% of their working time on the funded project. Applications go through a rigorous peer review process.
Dr. Brimble earned his PhD at University College London, where he studied DNA contamination in AAV viral vectors in the context of hemophilia. He then conducted postdoctoral research in the lab of Paul Thomas at St. Jude Children’s Research Hospital, studying T cell responses in patients treated with AAV gene therapy. His research looks broadly at the secondary consequences of gene therapy, including the fidelity of recombinant viral vectors and immune responses after dosing.
“This NBDF award provides crucial support at a career transition phase that will allow me to focus my new lab’s efforts on determining what parts of the AAV gene therapy T cells were responding to in samples from the first successful hemophilia B trial,” Dr. Brimble said. “Importantly, the funding will also allow us to expand the scope of the project with other collaborators within the hemophilia gene therapy field in a way that would not have otherwise been feasible.”